A commentary on the utility of a new L-DOPA-responsive dystonia mouse model

References

• Gorke W, Bartholome K. Biochemical and neurophysiological investigations in two forms of Segawa's disease. Neuropediatrics 1990; 21:3-8; PMID:1969123; http://dx.doi.org/10.1055/s-2008-1071448
   Google Scholar
• Ludecke B, Dworniczak B, Bartholome K. A point mutation in the tyrosine-hydroxylase gene associated with Segawa's syndrome. Hum Genet 1995; 95:123-125; PMID:7814018
   Google Scholar
• Ichinose H, Ohye T, Takahashi E, Seki N, Hori T, Segawa M, Nomura Y, Endo K, Tanaka H, Tsuji S et al. Hereditary progressive dystonia with marked diurnal fluctuation caused by mutations in the GTP cyclohydrolase I gene. Nat Genet 1994; 8:236-242; PMID:7874165; http://dx.doi.org/10.1038/ng1194-236
   Google Scholar
• Kurian MA, Gissen P, Smith M, Heales S, Clayton PT. The monoamine neurotransmitter disorders: an expanding range of neurological syndromes. Lancet Neurol 2011; 10:721-733; PMID:21777827; http://dx.doi.org/10.1016/S1474-4422(11)70141-7
   Google Scholar
• Wijemanne S, Jankovic J. Dopa-responsive dystonia-clinical and genetic heterogeneity. Nature reviews. Neurology 2015; 11(7):414-24; PMID:26100751
   Google Scholar
• Rajput AH, Gibb WG, Zhong XH, Shannak KS, Kish S, Chang LG, Hornykiewicz O. Dopa-responsive dystonia - pathological and biochemical observation in a case. Ann Neurol 1994; 35:396-402; PMID:7908789; http://dx.doi.org/10.1002/ana.410350405
   Google Scholar
• Furukawa Y, Nygaard TG, Gutlich M, Rajput AH, Pifl C, DiStefano L, Chang LJ, Price K, Shimadzu M, Hornykiewicz O et al. Striatal biopterin and tyrosine hydroxylase protein reduction in dopa-responsive dystonia. Neurology 1999; 53:1032-1041; PMID:10496263; http://dx.doi.org/10.1212/WNL.53.5.1032
   Google Scholar
• Clot F, Grabli D, Cazeneuve C, Roze E, Castelnau P, Chabrol B, Landrieu P, Nguyen K, Ponsot G, Abada M et al. Exhaustive analysis of BH4 and dopamine biosynthesis genes in patients with Dopa-responsive dystonia. Brain 2009; 132:1753-1763; PMID:19491146; http://dx.doi.org/10.1093/brain/awp084
   Google Scholar
• Longo N. Disorders of biopterin metabolism. J Inherit Metabol Dis 2009; 32:333-342; http://dx.doi.org/10.1007/s10545-009-1067-2
   Google Scholar
• Zafeiriou DI, Willemsen MA, Verbeek MM, Vargiami E, Ververi A, Wevers R. Tyrosine hydroxylase deficiency with severe clinical course. Mol Genet and Metab 2009; 97:18-20; http://dx.doi.org/10.1016/j.ymgme.2009.02.001
   Google Scholar
• Willemsen MA, Verbeek MM, Kamsteeg EJ, De Rijk-Van Andel JF, Aeby A, Blau N, Burlina A, Donati MA, Geurtz B, Grattan-Smith PJ et al. Tyrosine hydroxylase deficiency: a treatable disorder of brain catecholamine biosynthesis. Brain 2010; 133:1810-1822; PMID:20430833; http://dx.doi.org/10.1093/brain/awq087
   Google Scholar
• Fossbakk A, Kleppe R, Knappskog PM, Martinez A, Haavik J. Functional studies of tyrosine hydroxylase missense variants reveal distinct patterns of molecular defects in Dopa-responsive dystonia. Hum Mutat 2014; 35:880-890; PMID:24753243; http://dx.doi.org/10.1002/humu.22565
   Google Scholar
• Rose SJ, Yu XY, Heinzer AK, Harrast P, Fan X, Raike RS, Thompson VB, Pare JF, Weinshenker D, Smith Y et al. A new knock-in mouse model of L-DOPA-responsive dystonia. Brain 2015; 138(Pt 10):2987-3002; PMID:26220941
   Google Scholar
• Knappskog PM, Flatmark T, Mallet J, Ludecke B, Bartholome K. Recessively inherited L-DOPA-responsive dystonia caused by a point mutation(Q381K) in the tyrosine-hydroxylase gene. Hum Mol Genet 1995; 4:1209-1212; PMID:8528210; http://dx.doi.org/10.1093/hmg/4.7.1209
   Google Scholar
• Jinnah HA, Hess EJ, Ledoux MS, Sharma N, Baxter MG, Delong MR. Rodent models for dystonia research: characteristics, evaluation, and utility. Mov Disord 2005; 20:283-292; PMID:15641011; http://dx.doi.org/10.1002/mds.20364
   Google Scholar
• Krishnan V, Nestler EJ. Animal models of depression: molecular perspectives. Curr Top Behav Neurosci 2011; 7:121-147; PMID:21225412; http://dx.doi.org/10.1007/7854_2010_108
   Google Scholar
• Korner G, Noain D, Ying M, Hole M, Flydal MI, Scherer T, Allegri G, Rassi A, Fingerhut R, Becu-Villalobos D et al. Brain catecholamine depletion and motor impairment in a Th knock-in mouse with type B tyrosine hydroxylase deficiency. Brain 2015; 138:2948-2963; PMID:26276013; http://dx.doi.org/10.1093/brain/awv224
   Google Scholar
• Parenti G, Andria G, Valenzano KJ. Pharmacological Chaperone Therapy: Preclinical Development, Clinical Translation, and Prospects for the Treatment of Lysosomal Storage Disorders. Mol Ther 2015; 23:1138-1148; PMID:25881001; http://dx.doi.org/10.1038/mt.2015.62
   Google Scholar
• Underhaug J, Aubi O, Martinez A. Phenylalanine hydroxylase misfolding and pharmacological chaperones. Curr Top Med Chem 2012; 12:2534-2545; PMID:23339306; http://dx.doi.org/10.2174/1568026611212220008
   Google Scholar
• Marmolino D, Acquaviva F. Friedreich's Ataxia: from the (GAA)n repeat mediated silencing to new promising molecules for therapy. Cerebellum 2009; 8:245-259; PMID:19165552; http://dx.doi.org/10.1007/s12311-008-0084-2
   Google Scholar
• Albanese A, Bhatia K, Bressman SB, Delong MR, Fahn S, Fung VS, Hallett M, Jankovic J, Jinnah HA, Klein C et al. Phenomenology and classification of dystonia: a consensus update. Mov Disord 2013; 28:863-873; PMID:23649720; http://dx.doi.org/10.1002/mds.25475
   Google Scholar
• Jarman PR, Bandmann O, Marsden CD, Wood NW. GTP cyclohydrolase I mutations in patients with dystonia responsive to anticholinergic drugs. J Neurol Neurosurg Psychiatry 1997; 63:304-308; PMID:9328244; http://dx.doi.org/10.1136/jnnp.63.3.304
   Google Scholar
• Thenganatt MA, Jankovic J. Treatment of dystonia. Neurotherapeutics 2014; 11:139-152; PMID:24142590; http://dx.doi.org/10.1007/s13311-013-0231-4
   Google Scholar
• Jinnah HA, Factor SA. Diagnosis and treatment of dystonia. Neurol Clin 2015; 33:77-100; PMID:25432724; http://dx.doi.org/10.1016/j.ncl.2014.09.002
   Google Scholar
• Newman RP, LeWitt PA, Shults C, Bruno G, Foster NL, Chase TN, Calne DB. Dystonia: treatment with bromocriptine. Clin Neuropharmacol 1985; 8:328-333; PMID:3907823; http://dx.doi.org/10.1097/00002826-198512000-00003
   Google Scholar
• Stahl SM, Berger PA. Bromocriptine, physostigmine, and neurotransmitter mechanisms in the dystonias. Neurology 1982; 32:889-892; PMID:6124899; http://dx.doi.org/10.1212/WNL.32.8.889
   Google Scholar
• Quinn NP, Lang AE, Sheehy MP, Marsden CD. Lisuride in dystonia. Neurology 1985; 35:766-769; PMID:3887215; http://dx.doi.org/10.1212/WNL.35.5.766
   Google Scholar
• Bassi S, Ferrarese C, Frattola L, Sbacchi M, Trabucchi M. Lisuride in generalised dystonia and spasmodic torticollis. Lancet 1982; 1:514-515; PMID:6121171; http://dx.doi.org/10.1016/S0140-6736(82)91487-8
   Google Scholar
• Allen JA, Yost JM, Setola V, Chen X, Sassano MF, Chen M, Peterson S, Yadav PN, Huang XP, Feng B et al. Discovery of β-arrestin-biased dopamine D2 ligands for probing signal transduction pathways essential for antipsychotic efficacy. Proc Natl Acad Sci U S A 2011; 108:18488-18493; PMID:22025698; http://dx.doi.org/10.1073/pnas.1104807108
   Google Scholar
• Brust TF, Hayes MP, Roman DL, Burris KD, Watts VJ. Bias analyses of preclinical and clinical D2 dopamine ligands: studies with immediate and complex signaling pathways. J Pharmacol Exp Ther 2015; 352:480-493; PMID:25539635;http://dx.doi.org/10.1124/jpet.114.220293
   Google Scholar